2 completed, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Terminated 1 |
Follow Atriva Therapeutics GmbH: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib ATR-002, Placebo, Repaglinide - Healthy | Phase 1 | Completed | Atriva Therapeutics GmbH | 96 | 2022-06-23 | 2023-08-01 |
| Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19 ATR-002, Placebo - COVID-19 | Phase 2 | Terminated | Atriva Therapeutics GmbH | 133 | 2021-04-12 | 2022-09-22 |
| Phase 1 Study of ATR-002 ATR-002 MEK Inhibitor, Placebo oral tablet - Influenza | Phase 1 | Completed | Atriva Therapeutics GmbH | 70 | 2019-04-24 | 2020-05-13 |
COVID-19 (1) · Influenza, Human (1)
2-(2-chloro-4-iodophenylamino)-N-3,4-difluorobenzoic acid (2) · Celecoxib (1) · repaglinide (1)
Germany (2) · Belgium (1) · India (1) · Netherlands (1) · Poland (1) · Romania (1) · South Africa (1) · Spain (1)